Introduction
============

Adrenocortical carcinoma (ACC) is a rare disease with an estimated annual incidence of 0.7--2.0 per million population ([@bib1], [@bib2]). The prevalence of ACC varies depending on the circumstances under which patient data are collected. The reported frequency of ACC is derived from highly selected patient populations and may not reflect the prevalence rates observed in population-based studies. Combining the studies reported from 1982 to 2008, the ACC etiology of adrenal incidentaloma ranged from 0 to 14% ([@bib3], [@bib4], [@bib5], [@bib6], [@bib7]). Further, studies including patients with symptoms or signs caused by hormone excess or an abdominal mass showed a higher prevalence of ACC within the group of adrenal incidentalomas, 10--15% ([@bib8], [@bib9], [@bib10]). ACC can occur at any age, with a peak incidence between 40 and 50 years, and has a female predominance (55--60%) ([@bib2], [@bib11]). Most ACCs occur sporadically but rarely are related to various hereditary syndromes, including Li Fraumeni syndrome ([@bib12]), multiple endocrine neoplasia type 1 ([@bib13]), Beckwith--Wiedemann syndrome ([@bib14]), Lynch syndrome ([@bib15]), and others ([@bib16]). Moreover, at least 50--60% of those with ACC show clinical hormone excess; the most common form is hypercortisolism (Cushing syndrome) ([@bib17]).

Although the most common genetic alterations in ACC were *TP53* and*CTNNB1* mutations and *CDKN2A* and *ZNRF3* homozygous deletions ([@bib18]), the molecular and cellular mechanisms underlying the development of ACC have not been fully clarified; multi-omic studies demonstrated that only a minority of patients with ACC have pathogenic driver mutations ([@bib19], [@bib20]). Complete surgical removal can lead to cure ([@bib17]). However, the prognosis of ACC remains a challenge. The median overall survival (OS) of all patients with ACC is approximately 3--4 years; therapeutic outcomes are heterogeneous ([@bib17]). There are several known prognostic factors in patients with ACC, including clinical, pathological, and molecular factors ([@bib18]). Clinical prognostic factors include advanced tumor stage, cortisol excess, and older age ([@bib18]). In addition, poor prognosis is associated with pathologic factors, including tumor grade, mitotic count, Ki-67 proliferation index ([@bib21]), resection status ([@bib22]), and results of p53 and CTNNB1 immunohistochemistry ([@bib18]). Recently, progress in genomics has allowed research on the molecular prognostic markers of ACC ([@bib18]). Nonetheless, there is a paucity of data on recurrence or survival in Asian patients with ACC. Understanding of the clinical characteristics and prognostic stratification of ACC in the Asian population is essential for proper management.

Here, we investigated epidemiologic data including clinical manifestations and imaging/pathologic findings of patients with ACC in South Korea. Based on these results, we aimed to analyze the differences in characteristics according to remission, recurrence, and overall survival to identify prognostic factors of Asian patients with ACC.

Materials and methods
=====================

Data collection
---------------

We aimed to identify all patients aged 18 years and older diagnosed with or treated for ACC in South Korea and designed a patient cohort study with a retrospectively collected dataset. Among all 43 tertiary care institutions in South Korea, 25 participated in the data search for patients with ACC managed at their institutions. Multiple endocrinologists at each institution reviewed the medical records of all patients registered in this study to validate the diagnosis of ACC based on the following criteria: (1) diagnosed or treated by an endocrinologist between January 2000 and December 2014 and (2) reported by a pathologist via surgical resection or biopsy specimen. The registration process proceeded between June 2015 and March 2018. Patients with ACC were identified based on the following International Classification of Diseases, 10th revision (ICD-10) codes: C740 (primary malignant neoplasm of adrenal cortex, nonfunctioning adrenal carcinoma) and C749 (primary malignant neoplasm of adrenal gland, other type of adrenal cancer, unspecified adrenal cancer). Patients with metastasis to the adrenal gland were excluded.

The following data were collected from registered ACC patients: age at diagnosis, sex, BMI, date of last visit, managing institution, clinical symptoms at diagnosis, comorbidities, results of biochemical and hormonal tests to confirm tumor functionality, abdominal CT findings including size and pre-contrast Hounsfield unit (HU), pathologic findings including Ki-67 index and Weiss score, presence and location of distant metastasis at diagnosis, the first-line treatment modality, postoperative adjuvant therapy, and current progress including recurrence and mortality. Endocrinologists at each institution confirmed the presence of remission after surgery and the disease recurrence. Patient date of birth, initials, and home address were also collected to exclude duplicated subjects. In this study, the European Network for the Study of Adrenal Tumors (ENSAT)-staging system was used to evaluate clinical stage ([@bib9]) because, among all proposed classifications, this system may provide the best survival discrimination in patients with ACC ([@bib18]).

The institutional review board of each participating institution approved the current study based on the study protocol of Seoul National University Hospital (No.1505-051-671). The study was performed in accordance with the Declaration of Helsinki. The need to obtain informed consent from participants was waived due to the retrospective nature of this study.

Statistical analysis
--------------------

Data were analyzed using IBM SPSS, version 23.0 for Windows (SPSS Inc.). Continuous variables are presented as median (interquartile range, IQR). Categorical variables are presented as number (%). Comparisons between groups were conducted using chi-square test, Mann--Whitney *U* test, and Fisher's exact test. In addition, Cox proportional hazard model and log-rank tests were used to evaluate the prognosis of patients with ACC. Two-sided *P* values less than 0.05 were considered statistically significant.

Results
=======

Baseline characteristics and clinical manifestations of the study population
----------------------------------------------------------------------------

As shown in [Table 1](#tbl1){ref-type="table"}, 204 patients diagnosed with ACC from 25 hospitals were included in the study. The median follow-up duration was 20 months (IQR 5--52 months). The median age was 51.5 years (IQR 40--65.8 years) and female patients were dominant (*n* = 110, 53.9%). Among 188 patients with identifiable data of initial presentation at the time of diagnosis, 154 (81.9%) were symptomatic. The most common chief complaint was abdominal pain (*n* = 70, 40.2%), followed by palpable abdominal mass (*n* = 61, 33.9%). On abdominal CT images, the median tumor size was 85 mm (IQR 59--120 mm), with pre-contrast 34.4 HU (IQR 31.1--39.5 HU). Hypercortisolism (*n* = 62, 47.7%), elevated serum dehydroepiandrosterone-sulfate (DHEA-S; *n* = 21, 38.2%), elevated 24-h urine 17-ketosteroid (*n* = 16, 32.7%), and excessive aldosterone level (*n* = 14, 11.5%) within obtainable data. Table 1Demographic characteristics of patients with ACC (total *n* = 204).Available*n* (%)Median (IQR)Sex204 Male94 (46.1) Female110 (53.9)Age at diagnosis (years)20451.5 (40--65.8)BMI (kg/m^2^)14723.3 (21.2--25.5)Symptom and sign at diagnosis188154 (81.9) Abdominal pain17470 (40.2) Abdominal mass18061 (33.9) Edema15436 (23.4) Fatigue15534 (21.9) Weight loss16023 (14.4) Central obesity14921 (14.1)Underlying disease Hypertension19881 (40.9) Diabetes mellitus19740 (20.3) Other malignancy19520 (10.3) Osteoporosis17812 (6.7) Ischemic heart disease1918 (4.2) Arrhythmia1937 (3.6) Heart failure1936 (3.1) Stroke1914 (2.1)Functioning tumor13074 (56.9) Hypercortisolism13062 (47.7) Elevated serum DHEA-S5521 (38.2) Elevated 24hr urine 17-KS4916 (32.7) Aldosterone excess12214 (11.5)Abdominal CT finding Size (mm)18785 (59--120) Pre-contrast HU7334.4 (31.1--39.5) Right:Left:Bilateral19991:103:5 Heterogeneity (yes)154148 (96.1) Necrosis (yes)161104 (64.6) Calcification (yes)16240 (24.7) Hemorrhage (yes)16131 (19.3)[^2]

[Table 2](#tbl2){ref-type="table"} shows the prevalence of ACC based on the ENSAT staging system and pathologic findings. By the ENSAT staging system, stage 2 (*n* = 62, 30.4%) was the most common at the time of diagnosis, followed in order by stage 4 (*n* = 58, 28.4%), stage 3 (*n* = 35, 17.2%), and stage 1 (*n* = 19, 9.3%). There were 56 available data of distant metastasis with multiple answers allowed: 34 in the lung, 32 in the liver, 13 in the bone, 3 in the brain, and 1 in the pericardial metastasis. The number of crude incidence cases is presented in Supplementary Fig. 1 (see section on [supplementary materials](#supp1){ref-type="supplementary-material"} given at the end of this article). Table 2Stages and pathologic findings.Available*n* (%)Median (IQR)ENSAT stage174 119 (9.3) 262 (30.4) 335 (17.2) 458 (28.4) Unknown3030 (14.7)Pathology Weiss score61  ≤321 (34.4)  \>340 (65.6) Size (mm)147100 (64--130) Ki-67 index308 (4.5--16.3) Mitotic count (/50HPF)10010 (5--28.8) High nuclear grade (yes)6762 (92.5) Atypical mitosis (yes)7226 (36.1) Diffuse architecture (yes)4739 (83.0) Clear cell component (yes)6347 (74.6) Necrosis (yes)137122 (89.1) Venous invasion (yes)10752 (48.61) Sinusoidal invasion (yes)6023 (38.3) Capsular invasion (yes)12380 (65)[^3]

Treatment and overall prognosis
-------------------------------

[Figure 1](#fig1){ref-type="fig"} summarizes the prognosis of patients with ACC who had data for treatment modality using a flowchart. A total of 169 patients underwent surgery (84.1%), 149 of which were total adrenalectomy. Among 32 patients who did not undergo surgical treatment, 17 had identifiable data regarding one or more alternative palliative treatment methods: 5 for cytotoxic chemotherapy, 5 for mitotane therapy, 3 for both chemotherapy and mitotane, 3 for both mitotane and radiation therapy, and 1 for all three modalities. Figure 1Treatment and prognosis of patients with ACC. The figures in each box indicates the number of patients. After the first-line treatment, 102 patients reached remission state. Among those with remission, 49 cases of disease recurrence were reported during the follow-up period. There were 55 mortality cases in total, 10 from the group of the missing data of treatment information. No mortality case of death was reported in patients without recurrence. ACC, adrenocortical carcinoma; Tx, treatment.

After the first-line surgical treatment, 102 patients have reached remission of ACC, while 66 had remnant disease. Forty-nine cases of disease recurrence were reported during the follow-up period. In total cohort, there were 55 cases of mortality, which was most common in the non-remission group. Death was not reported in patients without recurrence.

Disease remission and recurrence
--------------------------------

There were 36 patients who had missing data for remission state; the remaining 168 patients were included in the analysis of remission and recurrence. In 168 patients who had follow-up records, 102 (60%) achieved remission. [Table 3](#tbl3){ref-type="table"} compares the characteristics of remission and remnant disease groups. Remission was more frequent in female patients (61.8 vs 42.4%, *P* = 0.017), patients without symptoms at diagnosis (26.5 vs 7.1%, *P* = 0.013), and patients without distant metastasis (95.6 vs 26.8%, *P* \< 0.001). The ENSAT stage was significantly different between the remission and non-remission groups: the proportion of stages 1--4 of remission-reached group was 14.3, 53.8, 27.5, and 4.4% in order, while that of remnant disease group was 5.4, 14.3, 7.1, and 73.2% (*P* for intergroup difference \<0.001). The remission group had smaller tumor size (91.5 mm vs 125 mm, *P* = 0.018) and lower mitotic count (9/50 HPF vs 19.5/50 HPF, *P* = 0.030) than the remnant disease group. Age, BMI, hormonal functionality, lymph node metastasis, and operation type did not show statistical differences. Table 3Characteristics and findings according to remission after first-line treatment (*n* = 168).Remission (+), *n* = 102Remission (−), *n* = 66*P* valueAvailable dataValue^a^Available dataValue^a^Age at diagnosis (years)10249.5 (39.0--63.0)6650 (38.5--61.3)0.961BMI (kg/m^2^)7523.1 (20.9--25.9)4723.3 (21.4--25.5)0.839Male10239 (38.2)6638 (57.6)0.017Initial symptom (yes)6850 (73.5)4239 (92.9)0.013Functional tumor (yes)7040 (57.1)4226 (61.9)0.694Distant metastasis (yes)914 (4.4)5641 (73.2)\<0.001Lymph node metastasis (yes)62 (33.3)4417 (38.6)1.000CT Tumor size (mm)9476.5 (54.8--114.8)61100 (65--140)0.009 Pre-contrast HU3635.0 (28.8--39.7)1834.4 (32.5--39.9)0.734Complete adrenalectomy (yes)10290 (88.2)5044 (88)1.000Pathology Weiss score424 (2--6)136 (4--7)0.103 Tumor size (mm)9291.5 (60.0--130.0)41125 (79.5--155)0.018 Ki67 index247.0 (3.5--10.8)320 (3--20)0.393 Mitotic count (/50HPF)629.0 (3.8--24.3)2819.5 (5.0--48.8)0.030ENSAT stage9156\<0.001 113 (14.3)3 (5.4) 249 (53.8)8 (14.3) 325 (27.5)4 (7.1) 44 (4.4)41 (73.2)Death (yes)7513 (17.3)5032 (64)\<0.001[^4][^5][^6]

Among 102 cases of remission during the follow-up period, there were 49 recurrent cases. As shown in [Table 4](#tbl4){ref-type="table"}, ACC recurrence was reported more in the female population (73.5 vs 50.9%, *P* = 0.019), with larger tumors (110 mm vs 80 mm, *P* = 0.007), in tumors with venous invasion (60.6 vs 24.2%, *P* = 0.006), and with higher mitotic count (15/50 HPF vs 5/50 HPF, *P* = 0.015). There was no significant difference between groups regarding initial presentation with symptoms or signs (67.6 vs 79.4%, *P* = 0.272) or ENSAT stage (*P* = 0.948): stages 1 to 4 accounted for 16.3, 51.0, 26.5, and 6.1% in non-recurrent group and 11.9, 57.1, 28.6, and 2.4% in recurrent group, respectively. Table 4Characteristics and findings according to presence of recurrence (*n* = 102).Recurrence (−), *n* = 53Recurrence (+), *n* = 49*P* valueAvailable dataValue^a^Available dataValue^a^Age at diagnosis (years)5350 (39--63)4948 (37.5--63.5)0.730BMI (kg/m^2^)4323.3 (20.9--25.9)3222.8 (20.9--25.9)0.748Male5326 (49.1)4913 (26.5)0.019Initial symptom (yes)3423 (67.6)3427 (79.4)0.272Functional tumor (yes)3620 (55.6)3420 (58.8)0.782CT5148 Right21 (41.2)17 (35.4)0.556 Left30 (58.8)31 (64.6) Tumor size (mm)4967 (51--96.5)45100 (58--120)0.008 Pre-contrast HU2135 (28--39.6)1534.3 (31--39.8)0.810 Necrosis (yes)4126 (63.4)4029 (72.5)0.381 Hemorrhage (yes)4010 (25.0)406 (15.0)0.264 Calcification (yes)4111 (26.8)418 (19.5)0.432ENSAT stage4942 18 (16.3)5 (11.9)0.948 225 (51.0)24 (57.1) 313 (26.5)12 (28.6) 43 (6.1)1 (2.4)Lymph node metastasis (yes)41 (25.0)21 (50.0)1.000Surgery5349 Complete adrenalectomy48 (90.6)42 (85.7)0.447 Partial adrenalectomy5 (9.4)7 (14.3)Adjuvant therapy after surgery (yes)5013 (26.0)4516 (35.6)0.313Pathology High nuclear grade (yes)2421 (87.5)2018 (90.0)1.000 Atypical mitosis (yes)266 (23.1)2010 (50.0)0.070 Diffuse architecture (yes)1412 (85.7)1714 (82.4)1.000 Clear cell component (yes)2216 (72.7)1814 (77.8)1.000 Necrosis (yes)3831 (81.6)4137 (90.2)0.338 Venous invasion (yes)338 (24.2)3320 (60.6)0.006 Sinusoid invasion (yes)215 (23.8)189 (50.0)0.108 Capsular invasion (yes)4323 (53.5)3726 (70.3)0.168 Weiss score204 (2--5)225 (3--7)0.174 Tumor size (mm)4780 (54--120)45110 (80--140)0.007 Ki 67 index136 (4--8)1110 (3--20)0.123 Mitotic count (/50HPF)295 (2--12)3315 (5--35)0.012Death (yes)350 (0)4013 (32.5)\<0.001[^7][^8]

Mortality
---------

Fifty-five deaths (27%) were reported during the follow-up period. The median OS of total cohort was as 145 months (95% CI 101.8 -- 188.2) and estimated 5-year OS rate was 64.5%. Among the total cohort, there were 174 cases with known ENSAT stage. There were 19 and 29 events in stages 1--3 and stage 4, respectively. Estimated 5-year OS rates were 91.7, 76.9, 78.3, and 30.3% from ENSAT stages 1 to 4, respectively. Kaplan--Meier curves and estimates of OS data according to ENSAT stage are plotted in [Fig. 2](#fig2){ref-type="fig"}. The median survival of stage 4 advanced disease was 19 months while that of less-advanced disease (stages 1--3) was 138.4 months, and the OS rates significantly differed (log-rank test, *P* \< 0.001). Figure 2Kaplan--Meier estimates of survival of patients with ACC according to ENSAT stage. Among a total cohort of 204 cases, 174 had known ENSAT stage. Median OS of these patients was 145 months (95% CI 101.8--188.2), and estimated 1-year, 2-year, and 5-year OS rates were 82.6, 75.0, and 64.5%, respectively. There were 19 and 29 events in stages 1--3 and 4, respectively. Mean survival of stages 1--3 was 138.4 months, and median survival of stage 4 was 19 months. ACC, adrenocortical carcinoma; CI, confidence interval; OS, overall survival.

Risk factors for mortality were assessed with univariable Cox proportional hazard models ([Table 5](#tbl5){ref-type="table"}). Since there were some missing values for variables regarding prognosis, it was not possible to create valid multivariable models due to small case numbers. For all-cause mortality, advanced ENSAT stage had the highest hazard ratio (HR) of 5.61 (95% CI 3.11--10.11), followed by sinus invasion in pathologic review (HR 5.50, 95% CI 1.93--15.71). The presence of lymph node metastasis, venous invasion, and capsular invasion were also statistically significant risk factors. Adrenalectomy was a protective factor (HR 0.11, 95% CI 0.06--0.19). Table 5All-cause mortality and ACC-specific mortality Cox models (univariable analysis).Event/available (*n*)HR95% CI*P* valueAll-cause mortality ENSAT stage 4 (vs stage 1--3)48/1745.613.11--10.11\<0.001 Lymph node metastasis (yes)32/652.451.19--5.050.016 Adrenalectomy (yes)55/2000.110.06--0.19\<0.001 Pathology  Venous invasion (yes)25/1072.671.17--6.060.019  Sinusoid invasion (yes)17/605.501.93--15.710.001  Capsular invasion (yes)27/1233.281.13--9.540.029ACC-specific mortality CT size42/1781.011.00--1.010.043 CT pre-contrast HU16/731.041.01--1.080.009 ENSAT stage 4 (vs. stage 1--3)38/1745.622.89--10.90\<0.001 Hypercortisolism (yes)25/1132.761.13--6.710.025 Lymph node metastasis (yes)25/652.811.22--6.470.015 Adrenalectomy (yes)44/2000.080.044--0.16\<0.001 Adjuvant therapy after surgery (yes)^a^9/954.761.19--19.030.027 Pathology  Venous invasion (yes)19/1073.291.24--8.710.016  Sinusoid invasion (yes)13/6012.772.81--58.030.001[^9][^10]

HR was also calculated for ACC-specific mortality in univariable analysis ([Table 5](#tbl5){ref-type="table"}). Sinusoid invasion had the highest HR of 12.77 (95% CI 2.81--58.03), followed by ENSAT stage 4 disease (HR 5.62, 95% CI 2.89--10.90). Large mass size, higher pre-contrast HU on CT, and tumor functionality (especially hypercortisolism) were additional risk factors for ACC-specific mortality.

Discussion
==========

ACC is an extremely rare but aggressive disease for which it is essential to obtain epidemiologic data, such as clinical characteristics and prognostic factors. The incidence rate of ACC was 0.5--2 cases per 1,000,000 person-years in previous reports ([@bib1], [@bib23]). In a population-based study conducted in the United States, Sharma *et al*. found that ACC incidence was higher in Caucasians, with a ratio of 6.3:1 ([@bib23]). While racial, ethnic, and regional differences may exist, underestimation of cases from hospitals that were not included in the survey could be another explanation for the low incidence rate (Supplementary Fig. 1). Additionally, the incidence rate has slightly increased in recent years. Recent high-resolution imaging studies and a nationwide health screening program could contribute to increased incidental identification of adrenal masses ([@bib24]). ACC was diagnosed more frequently in females and in the fifth decade, consistent with previous studies ([@bib2], [@bib22], [@bib25], [@bib26], [@bib27], [@bib28]).

The more symptomatic cases were observed in our study. There were 111 cases of abdominal pain and/or palpable abdominal mass as symptoms at diagnosis (59.4% of known information), which is a higher rate than previous studies. Iñiguez-Ariza *et al*. reported the mode of ACC discovery as follows: 42% incidentally found, 32% hormone excess, and 20% mass effect ([@bib29]). Several patients reported no symptoms even when the mass was larger than 8 cm. Since the data were collected by questionnaire retrospectively, the relationship between symptom and tumor size could not be concluded. In addition, our data contain the symptoms and signs at the time of diagnosis, which is not the same as the mode of ACC diagnosis. This point requires careful interpretation. In other words, it is hard to distinguish whether ACC was diagnosed due to the symptoms examined or whether ACC was found in testing for other symptoms or by accident in our dataset.

In diagnostic CT images, pre-contrast density was 34.4 HU, and median size was 85 mm. These findings were in accordance with known findings of ACC with higher pre-contrast HU and large size ([@bib30], [@bib31], [@bib32]). Mass heterogeneity, necrosis, calcification, and hemorrhage were also observed in CT images. There are previous reports on tumor laterality ([@bib26], [@bib33], [@bib34], [@bib35], [@bib36]), and left-side ACC was prevalent in the current study. ACC laterality is not fully explained in the current study. According to ENSAT stage ([@bib37]), the majority of patients in this cohort presented with stage 2 (30.4%) ACC, consistent with previous findings ([@bib32]). Common distant metastasis sites were lung, liver, and bone. Despite few (56 cases) identifiable records of the location of distant metastasis, the tendency of frequent metastatic sites was similar to previous studies ([@bib32], [@bib38], [@bib39], [@bib40], [@bib41], [@bib42]).

It is widely accepted that Weiss score of 3 or higher implies malignant potential of ACC, and Ki-67 index higher than 5% is only observed in malignancy. In the current study, there were 13 pathologic ACC cases with Weiss score of 1 or 2 and 11 cases with Ki-67 index of 1--5. We propose two possibilities for this result. First, there were some cases of Weiss score \<3 with aggressive disease course. Initially low-Weiss score tumors can progress to metastatic lesions during follow up. Pohlink *et al*. reported a case of Weiss 2 tumor that recurred 6 years later with lung metastases ([@bib43]), and Papotti *et al*. reported myxoid type ACC cases with low Weiss score ([@bib44]). Similarly, one patient with Weiss 2 score in our cohort showed distant metastasis at the time of diagnosis (ENSAT stage 4). Also, there were three patients with Weiss \<3 and ENSAT stage 3 and four patients with Weiss \<3 in whom the disease recurred after initial remission. Second, even though a higher Ki-67 index indicates malignant behavior, a low Ki-67 index does not always define benign behavior ([@bib45]). Stojadinovic *et al*. reported Ki-67 overexpression in 35.5% of ACC cases ([@bib46]). Our data include one ENSAT stage 4 patient with Ki-67 3%. These findings suggest that we should carefully evaluate and follow the progress of patients with low Weiss score and/or low Ki-67.

In Korea, surgical resection remains the mainstay of therapy, occurring in 84.1% of treated cases, consistent with other reports ([@bib21], [@bib23], [@bib40]). Surgical removal of primary disease is often curative and could yield survival benefits in advanced disease ([@bib21], [@bib40]). Of the 29 patients with information on adjuvant treatment modality, 4 received cytotoxic chemotherapy, 18 received mitotane, and 7 received radiation therapy. Data regarding mitotane dose, duration, and side effects were not included in the survey to determine therapeutic and adverse outcomes in a Korean ACC patient cohort. Although ACC was previously considered a radiotherapy-resistant disease, and there were contradictory results of adjuvant radiotherapy ([@bib47], [@bib48]), recent studies revealed 56--100% local disease control in the adjuvant setting ([@bib49], [@bib50], [@bib51], [@bib52]) without an advantage in OS. Radiation therapy should be considered in selected patients to prevent local recurrence.

In this study, all-cause mortality rate was 27%, and 5-year OS rate was 64.5%, which is higher than previous studies, stating 5-year OS rate of 35--48% ([@bib6], [@bib38], [@bib53], [@bib54], [@bib55], [@bib56]). Despite progress in understanding the molecular pathogenesis of ACC, tumor stage remains the main factor for predicting prognosis in patients with ACC. Five-year survival is reported to be 60--80% for tumors confined to the adrenal gland, 35--50% for locally advanced disease, and much lower in patients with metastatic disease (0--28%) ([@bib17], [@bib18], [@bib22], [@bib31], [@bib57], [@bib58]). As expected, higher ENSAT stage, lymph node metastasis, and the presence of venous, sinusoid, and capsular invasion were prognostic risk factors. Functioning tumors, especially ACC with cortisol excess, showed HR of 2.76 (95% CI 1.13--6.71, *P* = 0.025) for ACC-specific death but not for all-cause mortality. The poorer prognosis of cortisol-secreting tumors might be related to comorbidity with Cushing's syndrome and its possible immunosuppressive effects that may promote tumor development and metastasis ([@bib6], [@bib59]). Nevertheless, the effect of cortisol secretion on survival of patients with ACC remains uncertain ([@bib18]). Some studies reported that sex can affect survival rate ([@bib27], [@bib36], [@bib60]), but we found no such relationship in this cohort. Therefore, prospective research with long-term follow-up is required to investigate the risk factors linked to survival and prognosis in Asian patients with ACC.

The major strength of our study is that we analyzed ACC data in an Asian population. To our knowledge, this is the first nationwide multicenter cohort study of ACC conducted in Asia. Although ACC is a rare disease, this study was initiated with awareness of the demand for a Korean population-specific database. However, there were some limitations as well. First, because it was a retrospective registry-based study, there were missing data of several clinical variables. Multivariable Cox-proportional hazard models for disease outcome were not constructed due to this shortage, although multivariable models with risk factors would help to predict the prognosis for an individual case. Secondly, there were no detailed data on surgical resection type and not enough pathologic data which are considered prognostic factors. Data regarding Ki-67 index, an independent prognostic factor for predicting the survival of patients with ACC ([@bib18]), were insufficient because few hospitals performed the Ki-67 index test. Weiss score is also considered an informative factor to assess the prognosis of ACC; however, the majority of our data had partial data of Weiss score components or small number of Weiss score. Instead, we analyzed each pathologic characteristic as well as the Weiss score to make the best use of our dataset. Third, this study could not cover all incident ACC cases in Korea since 25 of 43 tertiary hospitals of the country participated in the survey. In addition, we consider the rather short duration of follow-up as another shortage of our study. Therefore, future studies should include more detailed data on surgical treatment and pathologic findings in longer duration.

In conclusion, we report the first patient-based cohort study of 204 cases of ACC in Korea. Higher ENSAT stage and advanced pathologic characteristics were risk factors for all-cause mortality, and large tumor size and cortisol-secreting tumor were additional risk factors for ACC-specific death. The results of the current study may help with disease prognostication in an Asian population. Prognostic factors of ENSAT stage 4, advanced pathologic characteristics, and cortisol excess were generally in accordance with previously reported Western-population-based research. Identifying such prognostic factors and risk stratification are essential for ACC treatment. In this context, patients with ACC should be managed by a multidisciplinary team including endocrinologists, surgeons, pathologists, oncologists, and radiologists.
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[^1]: \*(J S Lim and S-E Lee contributed equally to this work)

[^2]: 17-KS, 17-ketosteroid; ACC, adrenocortical carcinoma; BMI, body mass index; CT, computed tomography; DHEA-S, dehydroepiandosterone sulphate; HU, Hounsfield unit; IQR, interquartile range.

[^3]: ENSAT, European Network for Study of Adrenal Tumors; IQR, interquartile range.

[^4]: Chi-square test, Fischer's exact test, and Mann--Whitney *U* test were adopted for comparison.

[^5]: ^a^Continuous variables are presented as median (interquartile range), categorical variables as *n* (%).

[^6]: HPF, high power field.

[^7]: Chi-square test, Fisher's exact test, and Mann--Whitney *U* tests were adopted for comparison.

[^8]: ^a^Continuous variables are presented as median (interquartile range), categorical variables as *n* (%).

[^9]: Only statistically significant variables are listed.

[^10]: ^a^Adjuvant therapy was analyzed in patient with complete surgical removal.
